美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

The Health Care Select Sector SPDR Premium Income Fund

26.06

+0.35001.36%

成交量：5.03萬

成交額：131.05萬

市值：2,658.12萬

市盈率：- -

高：26.18

開：26.18

低：25.97

收：25.71

52周最高：27.35

52周最低：24.20

股本：102.00萬

流通股本：102.00萬

量比：0.44

換手率：4.93%

股息：3.27

股息率：12.54%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

Hims & Hers Health次季虧損超預期，轉向品牌減肥藥導致成本上升

美國銀行每年砸2.5億美元支持員工使用GLP-1減肥藥

安進二季度強勁藥品銷售，上調預期，將終止早期減肥藥研發

环球市场播报

創新藥研發加速遇「猴荒」

減肥藥重走PD-1老路，「白菜價藥王」要來？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/XLVI/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XLVI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVI\",,,,,undefined,":{"symbol":"XLVI","market":"US","secType":"STK","nameCN":"The Health Care Select Sector SPDR Premium Income Fund","latestPrice":26.06,"timestamp":1789415649881,"preClose":25.71,"halted":0,"volume":50329,"delay":0,"changeRate":0.01361338000777899,"floatShares":1020000,"shares":1020000,"eps":0,"marketStatus":"交易中","change":0.35,"latestTime":"09-14 15:56:07 EDT","open":26.18,"high":26.18,"low":25.9701,"amount":1310530.168185,"amplitude":0.008164,"askPrice":26.57,"askSize":700,"bidPrice":25.71,"bidSize":4,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":25.71,"sharesOutstanding":490000,"nav":25.680493,"aum":26194103.29,"dividendRate":0.125365,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.71,"preClose":25.71,"latestTime":"19:30 EDT","volume":15,"amount":385.59,"timestamp":1789169407403,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.442487},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVI\",,,,,undefined,":{"symbol":"XLVI","floatShares":1020000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.442487,"shares":1020000,"dividePrice":3.267,"high":26.18,"amplitude":0.008164,"preClose":25.71,"low":25.9701,"week52Low":24.2,"pbRate":"--","week52High":27.35,"institutionHeld":0,"latestPrice":26.06,"committee":-0.988636,"eps":0,"divideRate":0.125365,"volume":50329,"delay":0,"ttmEps":0,"open":26.18,"prevYearClose":26.4307,"prevWeekClose":25.71,"prevMonthClose":26.92,"prevQuarterClose":26.3599,"fiveDayClose":26.5969,"twentyDayClose":27.025,"sixtyDayClose":25.355},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLVI\",params:#limit:5,,,undefined,":[{"date":"2026-09-01","symbol":"XLVI","amount":0.284682,"announcedDate":"2026-08-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-01","defaultRemindTime":1788269400000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-03","payableDate":"2026-09-01","currency":"USD","dateTimestamp":1788235200000,"payDate":"2026-09-03"},{"date":"2026-08-03","symbol":"XLVI","amount":0.220362,"announcedDate":"2026-07-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-05","payableDate":"2026-08-03","currency":"USD","dateTimestamp":1785729600000,"payDate":"2026-08-05"},{"date":"2026-07-01","symbol":"XLVI","amount":0.265104,"announcedDate":"2026-06-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-01","defaultRemindTime":1782912600000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-06","payableDate":"2026-07-01","currency":"USD","dateTimestamp":1782878400000,"payDate":"2026-07-06"},{"date":"2026-06-01","symbol":"XLVI","amount":0.20398,"announcedDate":"2026-05-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-01","defaultRemindTime":1780320600000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-03","payableDate":"2026-06-01","currency":"USD","dateTimestamp":1780286400000,"payDate":"2026-06-03"},{"date":"2026-05-01","symbol":"XLVI","amount":0.266919,"announcedDate":"2026-04-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-05","payableDate":"2026-05-01","currency":"USD","dateTimestamp":1777608000000,"payDate":"2026-05-05"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLVI\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-02","recordDate":"2025-09-02","paymentDate":"2025-09-05","value":0.373503,"currency":"USD"},{"executeDate":"2025-10-01","recordDate":"2025-10-01","paymentDate":"2025-10-03","value":0.293409,"currency":"USD"},{"executeDate":"2025-11-03","recordDate":"2025-11-03","paymentDate":"2025-11-05","value":0.244969,"currency":"USD"},{"executeDate":"2025-12-01","recordDate":"2025-12-01","paymentDate":"2025-12-03","value":0.273076,"currency":"USD"},{"executeDate":"2025-12-29","recordDate":"2025-12-29","paymentDate":"2025-12-31","value":0.329285,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLVI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLVI\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","BK4588","AIPO","LFSC","BK1147","IBB","BIOY","BK4585","SBIO","BK0012","BK0028","BK1564","BK0188","BK0183","CHAT","PBE","WRND","ARTY","APXH","600958","QTOC","03958","BBP","BK0276","XLVI","VTHR","GSKH","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969925","title":"Hims & Hers Health次季虧損超預期，轉向品牌減肥藥導致成本上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969925","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658969925?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 11:46","pubTimestamp":1786419965,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MEDI","IYH","XLVI","THNR","PJP","FHLC","RSPH","FXH","PINK","CURE","NBDS","NVOC","TRUH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657896386","title":"美國銀行每年砸2.5億美元支持員工使用GLP-1減肥藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2657896386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657896386?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 17:06","pubTimestamp":1786007162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["THNR","LU0053666078.USD","LLYX","UYG","IE00B19Z3B42.SGD","BK4590","LU0211331839.USD","BAC","FTXO","LU0314106906.USD","GLP","IE0001KFT4U8.USD","KBWB","LU1506573853.SGD","BK4534","IE00BZ1G4Q59.USD","ELIS","FXH","LU0980610538.SGD","LLII","LLYZ","PJP","MEDI","IYF","LU0170899867.USD","RSPH","TFNS","JDOC","OZEM","LU0130103400.USD","XLVI","FHLC","VFH","NBDS","XLF","IYG","PGF","CURE","IYH","TRUH","LU1496350171.SGD","BK4588","ELIL","FNCL","LU0106831901.USD","IE00BBT3K403.USD","LU0648001328.SGD","PINK","LU1280957306.USD","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657674945","title":"安進二季度強勁藥品銷售，上調預期，將終止早期減肥藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2657674945","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657674945?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:11","pubTimestamp":1785877860,"startTime":"0","endTime":"0","summary":"　　$安进$公司于周二美股收盘后公布财报，第二季度强劲药品销售提振公司利润，因此上调了全年预期，但同时表示将终止一款早期减肥疗法的开发。　　这家生物技术公司周二表示，将停止AMG 513的开发，这是一款目前处于1期研究阶段的潜在减肥疗法。安进称，该研究将完成以跟踪已入组受试者。　　随着AMG 513开发的终止，安进在该领域唯一的候选药物是MariTide，该药目前正在进行针对肥胖、2型糖尿病和慢性体重管理等适应症的3期研究。","market":"fut","thumbnail":"https://static.tigerbbs.com/e910a0d7e1da6d4a41f6d581ee31760f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e910a0d7e1da6d4a41f6d581ee31760f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimezkz1673958.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4566","LU0320765992.SGD","IE00BJT1NW94.SGD","NBDS","PINK","IE00BFTCPJ56.SGD","BK4534","RSPH","NVOC","IBBQ","LU0109394709.USD","LU0058720904.USD","PBE","LU0889565916.HKD","LU0122379950.USD","LU2089984988.USD","BBH","LU0289739699.SGD","BK4581","IE0009355771.USD","LU1983299246.USD","IBB","LU1061106388.HKD","BK4139","TRUH","CURE","IE00B4R5TH58.HKD","MEDI","PJP","LU1571399168.USD","LU2242646821.SGD","THNR","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU2468319806.SGD","FXH","IYH","LU0868494617.USD","BK4533","IE00B2B36J28.USD","BK4588","LU2242652126.USD","SG9999001440.SGD","BK4599","TBXU","IE0002141913.USD","FHLC","XLVI","AMGN","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"創新藥研發加速遇「猴荒」","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WRND","BIOY","BK4585","GSKH","BBP","BK4588","IBB","GDOC","SBIO","LFSC","PBE","XLVI","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653874827","title":"減肥藥重走PD-1老路，「白菜價藥王」要來？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653874827","media":"健康凯歌","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653874827?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 09:23","pubTimestamp":1784683395,"startTime":"0","endTime":"0","summary":"一场减重大战，即将来临。走GCG/GLP-1双靶点路线的玛仕度肽，9毫克组60周减掉了18.55%。研究显示，80周最高剂量组减重28.3%，BMI≥35的对照组，104周减重甚至到了30.3%。此外，医保几轮谈判下来，PD-1的年治疗费用已经不要3万元，这已经不能单纯的算是降价了。疗效类似，再牛的“药王”也扛不住降价的仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8uwIsXpkDir","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["NBDS","THNR","LU1169590202.USD","PD","NVOC","FXH","XLVI","IYH","BK4023","LU1169589451.USD","PINK","PJP","TRUH","FHLC","MEDI","CURE","RSPH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":26,"code":"91000000","status":"200"}]}}